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Key Points
• Human splenic TFH expansion
during ITP participates in B-cell
differentiation and antiplatelet-
antibody production.
• IL-21 and CD40 are key
TFH molecules that could be
promising targets in the
treatment of ITP.
Antiplatelet-antibody-producingBcellsplayakey role in immune thrombocytopenia (ITP)
pathogenesis; however, little is known about T-cell dysregulations that support B-cell
differentiation. During the past decade, T follicular helper cells (TFHs) have been char-
acterized as the main T-cell subset within secondary lymphoid organs that promotes
B-cell differentiation leading to antibody class-switch recombination and secretion.
Herein, we characterized TFHs within the spleen of 8 controls and 13 ITP patients. We
showthathumansplenicTFHsare themainproducersof interleukin (IL)-21, expressCD40
ligand (CD154), andare locatedwithin thegerminal centerof secondary follicles.Compared
withcontrols, splenicTFH frequency ishigher in ITPpatientsandcorrelateswithgerminal
center and plasma cell percentages that are also increased. In vitro, IL-21 stimulation
combined with an anti-CD40 agonist antibody led to the differentiation of splenic B cells
into plasma cells and to the secretion of antiplatelet antibodies in ITP patients. Overall,
these results point out the involvement of TFH in ITP pathophysiology and the potential interest of IL-21 and CD40 as therapeutic
targets in ITP. (Blood. 2014;124(18):2858-2866)
Introduction
T follicular helper cells (TFHs) have been characterized as the main
CD41 T-cell subset that stimulates antibody production by antigen-
speciﬁc B cells within secondary lymphoid organs.1 Therefore, they
may play a key role in autoimmune diseases (AIDs), particularly the
ones supported by an aberrant humoral response such as immune
thrombocytopenia (ITP). TFH implication during autoimmunity
was ﬁrst demonstrated in murine models, particularly the sanroque
mice, which display a lupus-like phenotype associating glomeru-
lonephritis, lymphadenopathies, anti-DNA antibodies, anemia,
and ITP.2 Their secondary lymphoid organs show spontaneous
germinal center (GC) formation and plasma cell (PC) accumula-
tion because of TFH expansion.2,3 Indeed, the adoptive transfer of
splenic TFHs into the wild-type strain induces similar changes and
triggers the disease. Conversely, the inactivation of an adaptor
protein involved in T-cell receptor signaling, signaling lympho-
cytic activation molecule–associated protein (SAP), decreases
TFH, thus abrogating spontaneous GC formation and autoim-
mune manifestations.3 Although these data strongly argue for the
participation of TFHs to the stimulation of autoreactive B cells,
TFHs have not been studied in secondary lymphoid organs in humans
during AID, mostly because of accessibility issues. However, an
increase in CD41CXCR51 TFH-like cells has been observed in
blood during systemic lupus erythematosus4,5 and primary Sjo¨gren
syndrome.4,6 Interestingly, circulating TFH frequency correlates
with speciﬁc antibody titers, disease activity,4,6 circulating GC
B cells,5 and serum interleukin (IL)-21 levels.6 Circulating TFH
frequency is also increased during other antibody-mediated AIDs
such asmyasthenia gravis,7 granulomatosis with polyangeitis,8 and
bullous pemphigoid.9
Generated from naı¨ve T cells activated by antigen-presenting
dendritic cells, TFHs expressed the transcription factor B-cell lym-
phoma 6 protein (Bcl6) following the activation of the inducible
T-cell costimulatory (ICOS) pathway.10-12 Bcl6 leads to their follicu-
lar homingbyupregulating chemokineC-X-Cmotif receptor (CXCR)5
expression, while downregulating chemokine C-C motif receptor
(CCR)7. Thus, TFHs leaveT-cell areas13 and enter into the light zone
of GC where the ligand of CCR5, chemokine CXC motif ligand
(CXCL) 13, is produced by follicular dendritic cells (FDCs).14 TFH
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attraction into GC is also sustained by the autocrine production
of CXCL13.15 CXCR4 expression following TFH interaction
with FDCs drives them to the dark zone of GC.14,15 Once
activated, TFHs mainly produce IL-21, which maintains their
phenotype by inducing Bcl6 expression via an autocrine loop.16
On the contrary, the ligation of the programmed cell death protein-1
(PD-1) to its ligand PD-L1 expressed on B cells downregulates
ICOS and reduces IL-21 and IL-4 productions.17 Thus, TFH
phenotype is usually deﬁned as CD31CD41CXCR51ICOS1
PD-11CCR7low. The interactions of TFHs with B cells par-
ticipate in their differentiation into memory and PCs together
with immunoglobulin class-switch recombination.10 Thus, both
IL-212/2 and CD402/2 mice display an altered GC formation
with a low antibody production following antigen stimulation
because of a low PC differentiation.18,19 Similarly, treatment of
monkeys with an anti-CD40 antagonist antibody also disrupts
GC formation.20
ITP is an AID in which the humoral response plays a key role.21
Indeed, platelet destruction mostly relies on the phagocytosis of
platelets by splenic macrophages,22 which is facilitated by their
opsonization by autoantibodies targetingmembrane glycoproteins
(GPs) such as GPIIb/IIIa, GPIb/IX, and GPIa/IIa.23,24 Immuno-
globulin (Ig)G is the main isotype of antiplatelet antibodies,23
underlining class-switch recombination, a mechanism supported
by CD154 (CD40 ligand [CD40L]).19 Hitherto, circumstantial
evidence argues for a role for TFH in ITP, like changes of
expression within circulating T cells of several microRNAs that
target TFH markers such as CXCL13, IL-21, and Bcl6.25 More-
over, plasma CXCL1325 and IL-21 levels,26 which are both pro-
duced by TFHs, are higher in active ITP patients compared with
controls. Taken together with data from the murine model of
AID showing the major role of TFHs during autoimmunity, we
hypothesized that aberrant TFHs that recognized platelet antigens
could participate in the proliferation and differentiation of auto-
reactive B cells recruited into GC, thus favoring antiplatelet-
antibody production.
As spleen is the primary site of the autoimmune response during
ITP, we thought that TFHs, speciﬁcally localized in this secondary
lymphoid organ,would be of particular interest in the pathogenesis of
this AID. To date, TFHs have been characterized in tonsils1 during
chronic infections and, more recently, in lymph nodes during HIV.27
Only 2 publications assessed human splenic TFHs. In the ﬁrst report,
TFHs were hardly found within the spleens of 2 organ donors when
comparedwith the percentage observed in tonsils, probably because of
the absence of a sustained antigen stimulation.28 In the second report,
TFHswere quantiﬁed in the spleens of 6 ITPpatients and 6 controls by
assessing PD-1 expression by immunochemistry.29 PD-1–positive
cells tended to be less frequent in ITP patients comparedwith controls.
However, concomitant measurement of additional differentiation
markers is usually required to identify TFHs because PD-1 is also
expressed by activated non-TFH CD41 T cells30 and by regulatory
T follicular cells (TFRegs) that are decreased in the spleen of ITP
patients.29
Taking advantage of splenectomy as part of the treatment of
ITP, we quantiﬁed and localized TFHs within the spleen during a
B-cell–mediated AID. Given the importance of TFHs in promoting
B-cell differentiation, we assessed whether TFHs could participate
in the increase in secondary follicles and GC usually observed in
the spleen of ITP patients.31-33 Finally, we investigated the role of
CD154 and IL-21 expressed by TFHs in the stimulation of auto-
reactive B cells producing antiplatelet antibodies that are usually
abundantly found in the spleen during ITP.34,35
Methods
Patients
ITP patients, admitted to the university hospital of Dijon, France, were
enrolled in the study after givingwritten informed consent in accordancewith
the Declaration of Helsinki. The study was approved by the institutional
review board and the hospital ethics committee. Primary ITP patients were
included (ie, with a platelet count ,100 3 109/L and exclusion of familial,
viral, drug-induced thrombocytopenia and other AID-related thrombocyto-
penia). Treatments were initiated when platelet count was,303 109/L and/
or bleeding symptoms were observed, as recommended.36,37 Most of the
patients were treated with short-course steroids and, if necessary, intravenous
immunoglobulin (IVIg) as ﬁrst-line therapies, followed by dapsone. Splenec-
tomy was used as a second-line therapy 1 year after the disease onset, except
for a few patients for whom bleeding symptoms were unresponsive to ﬁrst-
line therapies. The spleens of 13 ITP patients were compared with 8 post-
traumatic spleens. Patients’ characteristics are reported in Table 1. No
difference was found regarding age and gender ratio between controls and
ITP patients. Peripheral blood mononuclear cells obtained from 10 patients
were comparedwith 5 controls. Tonsils (n5 4)were obtained from children
suffering recurrent infections. Tonsillectomies were performed at the
University Medical Center of Utrecht. The use of tonsils was approved by
the local ethics review committee.
Spleen preparation
Splenocytes were obtained as previously described32 and stored in liquid
nitrogen until needed. Cells were rapidly thawed and washed before use.
Flow cytometry (FCM)
The following antibodies were used for staining: CD3 alexaﬂuor700, CD4
allophycocyanin (APC)–H7, CD27 phycoerythrin (PE), CD84 PE, CD154
paciﬁc-blue, CXCR5 peridinin chlorophyll protein complex–cyanin (Cy)5.5,
CCR7 PE-Cy7 (Biolegend), ICOS APC, PD-1 ﬂuorescein isothiocyanate,
CD19 eFluor450, CD38 PE-Cy7 or APC (eBioscience), CD45RO PE-Cy7,
CD69PE, IgDﬂuorescein isothiocyanate,CXCR4PE, IL-21PE, andBcl6PE
(BD Biosciences). To measure CD154 expression, cells were cultured in
RPMI medium supplemented with 10% fetal calf serum and stimulated for
5 hours with phorbol-12-myristate-23-acetate (100 ng/mL) and ionomycin
(1 mg/mL). To assess IL-21 production, cells were stimulated similarly in
presence of brefeldin A (1mL/mL; BDBiosciences). At least 5003 103 cells
were incubated for 20 minutes with the appropriate antibodies or control
isotypes for membrane staining. Intracellular staining was performed after
cells were ﬁxed and permeabilized using the Foxp3/Transcription Factor
Staining Buffer Set (eBioscience) following the manufacturer’s instructions.
Data were acquired on a BDBiosciences LSRII cytometer and analyzed with
FlowJo software. MFI refers to the median ﬂuorescence intensity.
Table 1. Characteristics of splenectomized patients
Controls (n 5 8) ITP (n 5 13) P
Age, y 54.4 (26.9-65.8) 27.5 (22-52) .1
Gender ratio (female/male) 3/5 11/2 .06
Platelet count, 3109/L 191 (167-253) 22.5 (17-27) .0002
Disease duration, mo — 19.8 (11.9-42)
Previous treatments, n (%)
Steroids — 13 (100)
IVIg — 9 (69.2)
Dapsone — 8 (61.5)
Treatment within the 2 wk prior to splenectomy, n (%)
IVIg — 8 (61.5)
Steroids — 3 (23.1)
Dapsone — 1 (7.7)
None — 1 (7.7)
Responder to splenectomy, n (%) 12 (92.3)
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Cell separation
Splenocytes or peripheral blood mononuclear cells were incubated with CD4
or CD19 microbeads (Miltenyi) following fabricant’s instructions. Separa-
tions were performed with an AutoMACS (Miltenyi) device. Purity assessed
by FCM was.97%.
Gene expression quantification
RNA extraction was performed by using the RNeasy RNA-DNA-miRNA
Universal Kit (Qiagen) as recommended by themanufacturer. The expression
of CXCR5, CXCL13, BCL6, IL-21, and glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) messenger RNA (mRNA) was quantiﬁed by reverse
transcription quantitative polymerase chain reaction (RT-qPCR) by using
the following speciﬁc primer pairs: CXCR5, forward CTGGAGGACC
TGTTCTGGGA and reverse AGGAGGAAGATGAGGCTGTAG; IL-21,
forward GCCACATGATTAGAATGCGTC and reverse TTCAGGGAC
CAAGTCATTCAC;CXCL13, forwardGCTCAAGTCTGAACTCTACCTC
and reverse TCTCTTGGACACATCTACACCT; Bcl6, forward GCCCT
ATCCCTGTGAAATCTG and reverse GACGAAAGCATCAACACTCCA;
and GAPDH, forward ATGGGGAAGGTGAAGGTCG and reverse GGG
GTCATTGATGGCAACAATA. RT-qPCR was performed on a Quantstudio
12K real-time PCR system using the following thermal cycle conditions:
50°C for 2 minutes, 95°C for 10 minutes, 40 cycles at 95°C for 1 second, and
60°C for 30 seconds.Gene expression valueswere calculated according to the
comparative threshold cycle method38 using the stable expressed GAPDH
as endogenous control. The value of the lowest expressed sample was set as
1 and used to calculate fold change of target genes.
B-cell differentiation and antibody production
Splenic CD191B cells (1003 103 per well) were cultured in Iscovemodiﬁed
Dulbecco medium supplemented with 10% fetal calf serum in 96-well round
bottom plates. Cells were incubated with a combination of human IL-21
(100 ng/mL; Abcam), anti-IgM antibody (5 mg/mL; Jackson Immunor-
esearch Laboratories), and an anti-CD40 agonist antibody (5mg/mL;Bioceros).
B-cell subsets were determined by FCM at day 6. Total IgG (Human IgG
total Ready-SET-go; eBioscience) and anti-GPIIb/IIIa productions (PakAuto;
Immucor GTI) were measured in supernatants collected at day 10, following
the manufacturers’ instructions.
Immunochemistry
Anti-CD20, anti-CD4 (Dako, Glostrup, Denmark) and anti-PD-1 (Abcam,
Cambridge, United Kingdom) antibodies were used. Staining was per-
formed using a BenchMark Ultra instrument (Ventana Medical Systems,
Roche Diagnostic). Visualization was based on enzymatic conversion of
diaminobenzidine into a brown-colored precipitate by horseradish peroxidase
at the site of antigen localization.
Statistics
Excepted when speciﬁed, data are given by median (interquartile range). As
most of the data did not follow a Gaussian distribution, nonparametric tests
were used. Mann-Whitney test or Wilcoxon matched-pairs test were used to
compare quantitative data as appropriate. Fisher’s exact test was used to
compare qualitative data. Correlation analyses were performed by using
Spearman’s rank correlation test. P, .05 was considered signiﬁcant.
Results
TFHs are identified as CD31CD41CXCR51ICOS1PD-1hi within
human spleens
Splenic TFHs were characterized by FCM analyses as CXCR51
ICOS1PD-1hi cells among the CD31CD41 T cells (Figure 1A).
Their phenotype wasﬁrst screened formarkers known to be expressed
by TFHs and was compared with CD31CD41CXCR52 T cells
(Figure 1B). As expected, CD31CD41CXCR51ICOS1PD-1hi cells
expressed Bcl6 and were the main IL-21 producers among splenic
CD41 T cells. CD154 (CD40L), a costimulatory molecule involved
in class-switch recombination was preferentially expressed by
CD31CD41CXCR51ICOS1PD-1hi following polyclonal stim-
ulation. Splenic CD31CD41CXCR51ICOS1PD-1hi displayed a
memory phenotype consistent with a high expression of CD45RO,
whereas CD31CD41CXCR52 T cells were clearly divided into
naı¨ve (CD45RO2) and memory (CD45RO1) populations. CD31
CD41CXCR51ICOS1PD-1hi expressed the activation marker CD69
and highly expressed CD84, a homophilic adhesion molecule also
detected on B cells. CCR7 was weakly expressed by CD31CD41
CXCR51ICOS1PD-1hi, whereas CXCR4was expressed at a similar
level as splenic B cells (MFI: 484 [255-964]) vs 573 [437-690],
P5 .3), but not byCD41CXCR52Tcells (273 [226-330]; Figure1C).
IL-21R expression differed from one patient to another, with a
median expression of 22.5% (10.8-64) by CD31CD41CXCR51
ICOS1PD-1hi (Figure 1D), which was 4 times higher than CD41
CXCR52Tcells (5.8% [2.6-8.4],P, .0001). Taken together, these
results demonstrate that splenic CD31CD41CXCR51ICOS1PD-1hi
can be considered as TFHs with reference to their phenotype and
cytokine production. To our knowledge, human splenic TFHs have
been quantiﬁed by FCM only in a single study28 and were barely
observed compared with what is observed in tonsils. Herein, the
percentage of splenic TFHs represented 1.4% (0.5-2.6) of CD41
T cells, which was 10 times less than the frequency in tonsils (13.3%
[7-43], P 5 .003; Figure 1E), underlining speciﬁc features between
secondary lymphoid organs.
To further localizeTFHswithin the spleen, immunohistochemistry
was performed. Secondary follicles, characterized by their prom-
inent GC, were preferentially observed in ITP patients as shown by
CD20 staining (Figure 1F). Consistent with their CCR7lowCXCR41
CXCR51 phenotype, TFHswere locatedwithinGC, as shown by the
expression of PD-1 and CD4.
Splenic TFHs are expanded in ITP patients
The frequencies of splenic CD41CXCR51 cells from controls and
ITPpatientswere similar (18.7 [11.2-26.8] vs 20.8 [13.9-32.5],P5 .7)
(Figure 2A). However, the frequency of ICOS1PD-1hi amongCD41
CXCR51 cells was markedly higher in ITP patients than controls
(7.5 [4.9-15.2] vs 2.4 [1.9-3.6], P5 .004), resulting in an increase in
TFH percentage (CXCR51ICOS1PD-1hi) in ITP patients compared
with controls (2.04 [1.4-3.2] vs 0.5 [0.3-0.6], P 5 .003). TFH fre-
quency did not correlate with patient’s age (R 5 20.2, P 5 .4) or
treatment speciﬁcities (steroids or IVIg) received prior to splenec-
tomy (data not shown). To determine the proportion of TFRegs,
Foxp3 expression was measured in the spleen of 4 ITP patients and
represents a median of 8.8% (2.3% to 13%) of total TFH (data not
shown).
Toconﬁrm the results obtainedbyFCM,CXCR5mRNAexpression
was quantiﬁed in total splenic CD41 T cells (Figure 2B) and tended
to be higher in ITP patients comparedwith controls without reaching
the level of signiﬁcance (8.4 [4.7-13.2] vs 4.7 [3.8-5.8],P5 .07). In
parallel, the expression of CXCL13 and IL-21 mRNA, which are
both known to be produced by TFHs, was signiﬁcantly increased in
ITP patients as compared with controls (Figure 2B; 214 [57.3-418.2]
vs 34.9 [13.1-78.8], P 5 .02 and 12.8 [7.3-17.7] vs 4.4 [3.4-4.6],
P5 .009, respectively) and correlated with TFH percentage measured
by FCM (Figure 2C; R5 0.55, P5 .02 and R5 0.78, P5 .0004, res-
pectively). The expression of TFH master transcription factor BCL6
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did not consistently differ between groups but showed a trend to-
ward upregulation in ITP patients (Figure 2B). Indeed, it has been
shown that BCL6 mRNA quantiﬁcation did not account for Bcl6
protein expression and function, as Bcl6 expression is highly re-
gulated by translational and posttranslational mechanisms such
asBcl6 protein acetylation and phosphorylation, or its degradation.39
Circulating TFH and B-cell subset frequencies were determined
in 10 ITP patients. Data were compared with 5 healthy donors.
Although circulating TFHs represented only a small percentage of
CD41 T cells, their frequency was signiﬁcantly higher in ITP patients
comparedwith controls (0.1 [0.04-0.13], vs 0.01 [0.004-0.04],P5 .005;
Figure 2D). Neither difference betweenB-cell subsets in ITP patients
compared with controls, nor any correlation between circulating
TFH and B-cell subset percentages was observed (data not shown).
Splenic CD381 B-cell subsets are increased in ITP patients and
correlate with TFH percentage
To investigate the effect of splenic TFH expansion on B-cell differ-
entiation, we analyzed splenic B-cell subsets. B cells were identiﬁed
as CD191 cells, then subsets were deﬁned according to CD38 and
IgD expression (Figure 3A). PreGCB-cell (CD381IgD1), GCB-cell
(CD381IgD2), and PC (CD38hiIgD2) frequencies were higher in
ITP patients comparedwith controls (14.3 [12.3-24] vs 5.7 [3.8-10.6],
P5 .002; 11.6 [9.9-13.3] vs 4.8 [3-6.2],P5 .004 and 2.2 [1.6-2.8] vs
0.7 [0.4-1.3],P5 .003, respectively; Figure 3B). Except for memory
B-cell frequency (R 5 0.6, P 5 .01), no correlation was observed
between B-cell subset frequency and patient’s age (data not shown).
IL-21R was differentially expressed by B-cell subsets, with the
highest expression on PCs (Figure 3C). As TFHs participate inB-cell
differentiation, TFH and B-cell subset frequencies were compared.
Interestingly, TFH percentage positively correlated with GC B-cell
(R 5 0.7, P 5 .003), preGC B-cell (R 5 0.8, P 5 .0002), and PC
frequencies (R 5 0.7, P 5 .003; Figure 3D).
In vitro IL-21 and CD40 stimulations promote splenic B-cell
differentiation into GC B cells and PCs, leading to
antiplatelet-antibody secretion
To investigate which mechanisms were involved in the increase in
preGC and GC B cells and PCs in the spleen of ITP patients and to
address the potential implication of TFHs in B-cell differentiation,
the signals encountered by B cells in vivo were reproduced in vitro.
Sorted CD191 splenic B cells were stimulated with an anti-IgM
antibody to mimic B-cell receptor (BCR) ligation and with an anti-
CD40 agonist antibody to reproduce the effect of CD154 expressed
by TFHs. B cells were cultured with the combination of these anti-
bodies with or without IL-21, the main cytokine produced by TFHs.
The combination of IL-21 and CD40 ligation promoted GC B-cell
and PC differentiation both in ITP patients (Figure 4A) and controls
(data not shown) in a similar manner. In the presence of anti-CD40
antibody, IL-21 led to an increase in GCB-cell frequency from 4.4%
(2.2-9.1) to 23.4% (13.1-28.5) (P 5 .02; Figure 4B). BCR ligation
did not add much to the combined effect of IL-21 and CD40
stimulation. For PC differentiation, the addition of IL-21 to CD40
ligation increased their frequency from 0.3% (0.01-0.9) to 10.2%
(7.3-17.9) (P5 .004). Again, BCR ligation had only a minor effect.
Naı¨veB cells were themost prone to differentiate intoGCB cells and
PCs, as represented by their signiﬁcant decrease when IL-21 was
added to the culture. The most important decrease in naïve B cells
Figure 1. Splenic TFH phenotype and localization. (A) To determine splenic TFH percentage by FCM, CD31CD41 T cells were first gated within lymphocytes and then
discriminated for CXCR5 expression. Within CXCR51 T cells, the percentage of ICOS1PD-1hi cells was measured. (B) The expression of different markers was assessed
on CD31CD41CXCR51ICOS1PD-1hi (gray shaded histogram) and compared with CD31CD41CXCR52 (full line) and for some markers with B cells (dashed lined).
Representative histograms of 1 ITP patient are depicted; the dotted line represents isotype control. Cells were stimulated for 5 hours with phorbol-12-myristate-23-acetate
and ionomycin to determine CD154 expression, and in the presence of brefeldin A to measure IL-21 production. (C) CXCR4 expression was compared between
CD31CD41CXCR51ICOS1PD-1hi (TFHs), CD41CXCR52, and B cells. (D) The expression of IL-21R on TFHs was compared with CD41CXCR52. (E) TFH frequency within
tonsils (n5 4) was compared with the one in the spleens (6 controls and 13 ITP patients). Data are depicted in box-and-whisker graphs. P value derived by Mann-Whitney test.
(F) TFHs were localized by immunohistochemistry. Follicles and GC (arrowheads) were identified within the spleen by using CD20 staining. Then TFHs were identified by the
expression of PD-1 (black arrows) and CD4 (white arrows). Representative spleens of 1 control and 1 ITP patient (magnification 3200).
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was observed upon CD40 stimulation with and without BCR
stimulation (from 46.2% [37.2-55.5] to 15.2% [11.9-20.3], P5 .008
and from 46.8% [36-53.7] to 12.3% [9.4-25], P 5 .008, respec-
tively). A signiﬁcant increase in memory B-cell frequency was
observed when IL-21 was added to B cells stimulated or not with
anti-IgM (from 40.1% [33.7-47.2] to 52.7% [47.9-58.3], P 5 .008
and from 40.8% [36.2-48.2] to 49.4% [45.9-54.4], P 5 .02, res-
pectively), but not anymore when anti-CD40 was added (38.55%
[32.7-45.5] vs 39.6% [37-44], P5 .9 and 34% [25.1-43.9] vs 45.4%
[41.6-53.3], P 5 .08, respectively), probably because the differen-
tiation into PCs was favored in this condition. Both in controls and
ITP patients, IgGswere only detected in culture supernatants when
PC differentiation was obtained (ie, in presence of IL-21 with
CD40 ligation) (Figure 5A). Interestingly, anti-GPIIb/IIIa antibodies
were only detected in ITP patients when splenic B cells were
concomitantly stimulated with IL-21 and anti-CD40 (Figure 5B).
Discussion
During ITP, the spleen is the primary site for the activation of B cells
producing antiplatelet antibodies and where most of the activated
T cells that recognized antiplatelet antigens are located.35 However,
the interactions between T and B cells in the spleen have not
been investigated yet. Although the involvement of TFHs in the
pathogenesis of AIDs has clearly been demonstrated in murine
models,2,3 limited knowledge describes their role in human secondary
Figure 2. TFH quantification and mRNA expression. (A) The percentage of CXCR51 among CD31CD41, of ICOS1PD-1hi within CD31CD41CXCR51 T cells and the
percentage of TFHs defined as CD31CD41CXCR51ICOS1PD-1hi were determined in 6 controls (open circles) and 13 ITP (black squares). Data are summarized in dot plots.
(B) CXCR5, CXCL13, BCL6, and IL-21 mRNA expression was quantified by RT-qPCR in total splenic CD41 T cells of controls (n 5 7, open circles) and ITP (n 5 12, black
squares). Results are expressed as fold change (FC) after normalization on GAPDH expression. Data are summarized in dot plots. The horizontal bar represents the median
with interquartile range. P value derived by Mann-Whitney test. (C) The expression of CXCL13 and IL-21 was correlated with TFH percentage measured by FCM. Spearman’s
rank correlation coefficient (R) and P value are depicted. Line represents linear regression. (D) Circulating TFH frequency in 5 controls (open circles) and 10 ITP patients (black
squares) is summarized in dot plots. The horizontal bar represents the median with interquartile range. P value derived by Mann-Whitney test.
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lymphoid organs, as TFHs have been mainly characterized in blood
during AIDs.4-9 Herein, we quantiﬁed for the ﬁrst time splenic TFHs
by FCM in accordance with the phenotype currently used in the
literature (ie, CD31CD41CXCR51ICOS1PD-1hi).10 Accordingly,
splenic TFHs also expressed the transcription factor Bcl6, displayed
a central memory phenotype (CD45RO1CCR72), and were in an
activated state (CD691). TFHs highly expressed CD84, a SAP
that facilitates prolonged contact with B cells that also expressed
CD84.40 Upon stimulation, TFHs expressed CD154 (CD40L) and
were the main producers of IL-21 among splenic CD41 T cells.
Splenic TFH frequency was increased during ITP, an antibody-
mediated AID, corroborating results observed in sanroque mice.
This increase correlated with a higher CXCL13 (CXCR5 binding
chemokine) expression among CD41 splenic T cells, a chemokine
produce by TFHs, but also by FDCs, that favors the recruitment of
CXCR51 cells (ie, TFHs and B cells).41 In addition, splenic TFHs
highly expressed CXCR4, in accordance with their location within
the GC of secondary follicles during ITP.Most TFHswere proinﬂam-
matory cells, as only a few of them expressed Foxp31 in accordance
with a previous report showing a decrease in splenic TFRegs in ITP.29
We subsequently demonstrated that the described expansion
of TFHs could be involved in B-cell differentiation in the spleen
of ITP patients, contributing to the development of PCs produc-
ing antiplatelet autoantibodies. As a ﬁrst line of evidence and in
agreement with previous reports,32,33 the increased number of TFHs
was concomitant to an expansion of GC in ITP patients related to an
increase in bothGCB cells and PCs. Supporting the role of TFHs in
the generation of GC, we demonstrated that TFHs were the major
source of IL-21 in ITP spleen, a key cytokine involved in B-cell
stimulation and differentiation.42 Interestingly, IL-21 expression
in splenic CD41 T cells correlates with TFH abundance, and the
stimulation of B cells with IL-21 in the presence of CD40 engage-
ment induces their differentiation in PCs and the secretion of anti-
platelet antibodies. These results are perfectly in line with what has
been reported on circulatingB cells42 and account for what is observed
in vivo in ITP spleens. Taken togetherwith a previous report showing
plasma IL-21 increase during ITP,43 our results point out IL-21 pro-
duced by TFH as a potential new therapeutic target during ITP.
Indeed, the role of IL-21 in the pathogenesis of various AIDs with
an abnormal humoral response in humans, such as systemic lupus
erythematosus4,5 and rheumatoid arthritis,44 has been demonstrated
and has justiﬁed the use of anti-IL-21 therapy in clinical trials.45
However, the fact that bone marrow PCs, contrary to secondary
lymphoid organ PCs, do not depend on IL-21 to survive,46 argues
for a blockade of the IL-21 axis early in the disease, before the
establishment of long-lived PCs. Moreover, IL-21 synergistically
acts with IL-15 to activate CD81 T cells and to increase interferon-g
secretion.47 Based on reports showing that cytotoxic T cells partici-
pate in platelet destruction48 and that splenic IFN-g1CD81 T cells
are increased in some ITP patients,49 it can be assumed that IL-21
antagonism could also abrogate their effects. Because T helper 17
cells (Th17) and natural killer T cells also produce IL-21,50 their
frequencies were measured, and these cells represented only
0.05% of CD41 T cells32 and 0.005% of CD31 T cells, respectively
Figure 3. Splenic B-cell subset phenotype and quantification. (A) B-cell subsets (naı¨ve, memory, GC, pregerminal center [preGC], and PCs) were determined among
CD191 splenocytes by the expression of CD38 and IgD. Representative quantile contour plot of 1 ITP patient. (B) B-cell subset percentages were compared between 6
controls (open circles) and 11 ITP patients (black squares). Results are summarized in dot plots. The horizontal bar represents the median with interquartile range. P value
derived by Mann-Whitney test. (C) The expression of IL-21R was assessed on B-cell subsets. IL-21R MFI measured in 6 controls and 11 ITP patients is depicted in dot plots.
The horizontal bar represents the median with interquartile range. P value derived by Mann-Whitney test. *P , .05; ***P , .001. (D) TFH percentages correlate with the
percentages of GC B cells, preGC B cells, and PCs. The graphs represent the results obtained in 6 controls (open circles) and 11 ITP patients (black squares). Spearman’s
rank correlation coefficient (R) and P value are depicted. Line represents linear regression.
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(data not shown). AsTFHswere 30 to 300 timesmore frequent, they
may be the major source of IL-21 in the spleen of ITP patients.
Importantly, TFHs also expressed CD154 upon activation, and
CD40 ligation on splenic B cells participates in their differentiation
into PCs and to the production of antiplatelet antibodies in ITP
patients. These results support the beneﬁcial effects of the disruption
of the CD40/CD154 axis in ITP shown in previous studies. Indeed,
treatmentwith anti-CD154monoclonal antibody resulted in a decrease
in B cells producing antiplatelet antibodies.51 In a phase 1/2 study
conducted on 46 chronic ITP patients, a 24% overall response
rate was obtained after treatment by 2 humanized anti-CD154
antibodies.52 However, further clinical studies using these anti-
bodies were interrupted because of an increased risk of thromboem-
bolic events, partly because of the activation of platelets that express
CD154.53,54 To counteract this effect, therapeutic antibodies that
antagonize CD40 have been tested with promising results in
Figure 4. Role of IL-21 and CD40 ligation in splenic B-cell differentiation and total IgG production. Sorted splenic CD191 B cells were stimulated with a combination of
anti-IgM antibody (aIgM), anti-CD40 agonist antibody (aCD40), and IL-21. At day 6, cells were stained for the determination of B-cell subsets using CD38 and IgD expression.
(A) Quantile contour plots of 1 representative ITP patient are depicted with the percentages of PCs and GC, preGC, memory (mem.), and naive B cells. (B) The effect of each stimulation
alone or in combination on B-cell subsets is summarized in dot plots. Results obtained from 3 controls (open circles) and 5 ITP patients (black squares). P value derived by Wilcoxon
matched-pairs test. The horizontal bar represents the median with interquartile range. P value derived by Wilcoxon matched-pairs test. NS, nonsignificant; *P , .05; **P , .01.
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animal models20 and in human AIDs such as Crohn’s disease55
and could become a therapeutic approach in ITP.
It should be stressed that the changes in TFH and B-cell subset
frequencies observed in the spleen of ITP patients might be because
of treatments received prior to splenectomy, particularly IVIg.
Nevertheless, this hypothesis appears very unlikely as it has recently
been shown in a model of collagen-induced arthritis that IVIg therapy
leads to a decrease in TFH and B-cell differentiation, whereas TFRegs
are increased.56 Of importance, complete response to this question
requires the assessment of the spleen from ITP patientswho responded
to medical therapy, which is impossible as these patients do not
undergo splenectomy. Conversely, the increase in TFH associated
with B-cell differentiation is more likely to be because of chronic
antigen stimulation (ie, platelet GPs during ITP), similarly to what is
observed in tonsils during chronic bacterial infection1 or in lymph
nodes during HIV infection.27 Thus, our results support a role for
TFH in B-cell recruitment and differentiation in the spleen of ITP
patients rather than modulations induced by treatment.
Whether the change in splenic TFH frequency directly supports
ITP or represents a consequence of the underlying inﬂammatory
process is a matter of debate. However, our data showed IL-21 and
CD154 as key factors of B-cell differentiation and antiplatelet-
antibody production. Even though the effect of TFHs on B cells was
not directly assessed in a coculture system, CD154 is expressed
by TFHs, and these cells are the main producers of IL-21 within the
spleen. Moreover, animal models like the sanroque model clearly
argue for the direct involvement of TFHs in autoimmunity as their
adoptive transfer intowild-typemouse leads to aberrant GC formation
and triggers autoimmune manifestations that are abrogated when
T-cell receptor signaling is disrupted.3
During recent years, evidence for a role of TFHs during AIDS in
humans has been increasing. We here report for the ﬁrst time in ITP
an increase in splenic TFHs. Although a role of the inﬂammatory
environment in the increase inTFH frequency could not be completely
excluded, our data strongly suggest that TFHs participate in B-cell
differentiation and antiplatelet-antibody production through IL-21
secretion and by the interaction of CD154 with CD40. Thereby,
IL-21 and CD40 could be promising therapeutic targets during ITP
and more generally during antibody-mediated AID.
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